[{"path":"https://ahasoplakus.github.io/clinTables/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Sukalpo Saha. Maintainer, author.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Saha S (2023). clinTables: Clinical Trial Tables R. R package version 0.0.0.9002, https://github.com/ahasoplakus/clinTables/.","code":"@Manual{,   title = {clinTables: Clinical Trial Tables in R},   author = {Sukalpo Saha},   year = {2023},   note = {R package version 0.0.0.9002},   url = {https://github.com/ahasoplakus/clinTables/}, }"},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"our-pledge","dir":"","previous_headings":"","what":"Our Pledge","title":"Contributor Covenant Code of Conduct","text":"members, contributors, leaders pledge make participation community harassment-free experience everyone, regardless age, body size, visible invisible disability, ethnicity, sex characteristics, gender identity expression, level experience, education, socio-economic status, nationality, personal appearance, race, caste, color, religion, sexual identity orientation. pledge act interact ways contribute open, welcoming, diverse, inclusive, healthy community.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"our-standards","dir":"","previous_headings":"","what":"Our Standards","title":"Contributor Covenant Code of Conduct","text":"Examples behavior contributes positive environment community include: Demonstrating empathy kindness toward people respectful differing opinions, viewpoints, experiences Giving gracefully accepting constructive feedback Accepting responsibility apologizing affected mistakes, learning experience Focusing best just us individuals, overall community Examples unacceptable behavior include: use sexualized language imagery, sexual attention advances kind Trolling, insulting derogatory comments, personal political attacks Public private harassment Publishing others’ private information, physical email address, without explicit permission conduct reasonably considered inappropriate professional setting","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"enforcement-responsibilities","dir":"","previous_headings":"","what":"Enforcement Responsibilities","title":"Contributor Covenant Code of Conduct","text":"Community leaders responsible clarifying enforcing standards acceptable behavior take appropriate fair corrective action response behavior deem inappropriate, threatening, offensive, harmful. Community leaders right responsibility remove, edit, reject comments, commits, code, wiki edits, issues, contributions aligned Code Conduct, communicate reasons moderation decisions appropriate.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"scope","dir":"","previous_headings":"","what":"Scope","title":"Contributor Covenant Code of Conduct","text":"Code Conduct applies within community spaces, also applies individual officially representing community public spaces. Examples representing community include using official e-mail address, posting via official social media account, acting appointed representative online offline event.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"enforcement","dir":"","previous_headings":"","what":"Enforcement","title":"Contributor Covenant Code of Conduct","text":"Instances abusive, harassing, otherwise unacceptable behavior may reported community leaders responsible enforcement Sukalpo Saha. complaints reviewed investigated promptly fairly. community leaders obligated respect privacy security reporter incident.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"enforcement-guidelines","dir":"","previous_headings":"","what":"Enforcement Guidelines","title":"Contributor Covenant Code of Conduct","text":"Community leaders follow Community Impact Guidelines determining consequences action deem violation Code Conduct:","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"1-correction","dir":"","previous_headings":"Enforcement Guidelines","what":"1. Correction","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Use inappropriate language behavior deemed unprofessional unwelcome community. Consequence: private, written warning community leaders, providing clarity around nature violation explanation behavior inappropriate. public apology may requested.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"2-warning","dir":"","previous_headings":"Enforcement Guidelines","what":"2. Warning","title":"Contributor Covenant Code of Conduct","text":"Community Impact: violation single incident series actions. Consequence: warning consequences continued behavior. interaction people involved, including unsolicited interaction enforcing Code Conduct, specified period time. includes avoiding interactions community spaces well external channels like social media. Violating terms may lead temporary permanent ban.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"3-temporary-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"3. Temporary Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: serious violation community standards, including sustained inappropriate behavior. Consequence: temporary ban sort interaction public communication community specified period time. public private interaction people involved, including unsolicited interaction enforcing Code Conduct, allowed period. Violating terms may lead permanent ban.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"4-permanent-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"4. Permanent Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Demonstrating pattern violation community standards, including sustained inappropriate behavior, harassment individual, aggression toward disparagement classes individuals. Consequence: permanent ban sort public interaction within community.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/CODE_OF_CONDUCT.html","id":"attribution","dir":"","previous_headings":"","what":"Attribution","title":"Contributor Covenant Code of Conduct","text":"Code Conduct adapted Contributor Covenant, version 2.1, available https://www.contributor-covenant.org/version/2/1/code_of_conduct.html. Community Impact Guidelines inspired [Mozilla’s code conduct enforcement ladder][https://github.com/mozilla/inclusion]. answers common questions code conduct, see FAQ https://www.contributor-covenant.org/faq. Translations available https://www.contributor-covenant.org/translations.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/index.html","id":"clintables-","dir":"","previous_headings":"","what":"Clinical Trial Tables in R","title":"Clinical Trial Tables in R","text":"clinTables shiny application visualize standard tables used Clinical Trials Find app : clinTables","code":""},{"path":"https://ahasoplakus.github.io/clinTables/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"Clinical Trial Tables in R","text":"Latest dev version Run library(clinTables) access exported functions clinTables help reproducing analysis performed app. , can run application locally using:","code":"remotes::install_github(\"ahasoplakus/clinTables\") # Launch the application run_app()"},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":null,"dir":"","previous_headings":"","what":"Apache License","title":"Apache License","text":"Version 2.0, January 2004 <http://www.apache.org/licenses/>","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"1-definitions","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"1. Definitions","title":"Apache License","text":"“License” shall mean terms conditions use, reproduction, distribution defined Sections 1 9 document. “Licensor” shall mean copyright owner entity authorized copyright owner granting License. “Legal Entity” shall mean union acting entity entities control, controlled , common control entity. purposes definition, “control” means () power, direct indirect, cause direction management entity, whether contract otherwise, (ii) ownership fifty percent (50%) outstanding shares, (iii) beneficial ownership entity. “” (“”) shall mean individual Legal Entity exercising permissions granted License. “Source” form shall mean preferred form making modifications, including limited software source code, documentation source, configuration files. “Object” form shall mean form resulting mechanical transformation translation Source form, including limited compiled object code, generated documentation, conversions media types. “Work” shall mean work authorship, whether Source Object form, made available License, indicated copyright notice included attached work (example provided Appendix ). “Derivative Works” shall mean work, whether Source Object form, based (derived ) Work editorial revisions, annotations, elaborations, modifications represent, whole, original work authorship. purposes License, Derivative Works shall include works remain separable , merely link (bind name) interfaces , Work Derivative Works thereof. “Contribution” shall mean work authorship, including original version Work modifications additions Work Derivative Works thereof, intentionally submitted Licensor inclusion Work copyright owner individual Legal Entity authorized submit behalf copyright owner. purposes definition, “submitted” means form electronic, verbal, written communication sent Licensor representatives, including limited communication electronic mailing lists, source code control systems, issue tracking systems managed , behalf , Licensor purpose discussing improving Work, excluding communication conspicuously marked otherwise designated writing copyright owner “Contribution.” “Contributor” shall mean Licensor individual Legal Entity behalf Contribution received Licensor subsequently incorporated within Work.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"2-grant-of-copyright-license","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"2. Grant of Copyright License","title":"Apache License","text":"Subject terms conditions License, Contributor hereby grants perpetual, worldwide, non-exclusive, -charge, royalty-free, irrevocable copyright license reproduce, prepare Derivative Works , publicly display, publicly perform, sublicense, distribute Work Derivative Works Source Object form.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"3-grant-of-patent-license","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"3. Grant of Patent License","title":"Apache License","text":"Subject terms conditions License, Contributor hereby grants perpetual, worldwide, non-exclusive, -charge, royalty-free, irrevocable (except stated section) patent license make, made, use, offer sell, sell, import, otherwise transfer Work, license applies patent claims licensable Contributor necessarily infringed Contribution(s) alone combination Contribution(s) Work Contribution(s) submitted. institute patent litigation entity (including cross-claim counterclaim lawsuit) alleging Work Contribution incorporated within Work constitutes direct contributory patent infringement, patent licenses granted License Work shall terminate date litigation filed.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"4-redistribution","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"4. Redistribution","title":"Apache License","text":"may reproduce distribute copies Work Derivative Works thereof medium, without modifications, Source Object form, provided meet following conditions: () must give recipients Work Derivative Works copy License; (b) must cause modified files carry prominent notices stating changed files; (c) must retain, Source form Derivative Works distribute, copyright, patent, trademark, attribution notices Source form Work, excluding notices pertain part Derivative Works; (d) Work includes “NOTICE” text file part distribution, Derivative Works distribute must include readable copy attribution notices contained within NOTICE file, excluding notices pertain part Derivative Works, least one following places: within NOTICE text file distributed part Derivative Works; within Source form documentation, provided along Derivative Works; , within display generated Derivative Works, wherever third-party notices normally appear. contents NOTICE file informational purposes modify License. may add attribution notices within Derivative Works distribute, alongside addendum NOTICE text Work, provided additional attribution notices construed modifying License. may add copyright statement modifications may provide additional different license terms conditions use, reproduction, distribution modifications, Derivative Works whole, provided use, reproduction, distribution Work otherwise complies conditions stated License.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"5-submission-of-contributions","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"5. Submission of Contributions","title":"Apache License","text":"Unless explicitly state otherwise, Contribution intentionally submitted inclusion Work Licensor shall terms conditions License, without additional terms conditions. Notwithstanding , nothing herein shall supersede modify terms separate license agreement may executed Licensor regarding Contributions.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"6-trademarks","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"6. Trademarks","title":"Apache License","text":"License grant permission use trade names, trademarks, service marks, product names Licensor, except required reasonable customary use describing origin Work reproducing content NOTICE file.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"7-disclaimer-of-warranty","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"7. Disclaimer of Warranty","title":"Apache License","text":"Unless required applicable law agreed writing, Licensor provides Work (Contributor provides Contributions) “” BASIS, WITHOUT WARRANTIES CONDITIONS KIND, either express implied, including, without limitation, warranties conditions TITLE, NON-INFRINGEMENT, MERCHANTABILITY, FITNESS PARTICULAR PURPOSE. solely responsible determining appropriateness using redistributing Work assume risks associated exercise permissions License.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"8-limitation-of-liability","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"8. Limitation of Liability","title":"Apache License","text":"event legal theory, whether tort (including negligence), contract, otherwise, unless required applicable law (deliberate grossly negligent acts) agreed writing, shall Contributor liable damages, including direct, indirect, special, incidental, consequential damages character arising result License use inability use Work (including limited damages loss goodwill, work stoppage, computer failure malfunction, commercial damages losses), even Contributor advised possibility damages.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"9-accepting-warranty-or-additional-liability","dir":"","previous_headings":"Terms and Conditions for use, reproduction, and distribution","what":"9. Accepting Warranty or Additional Liability","title":"Apache License","text":"redistributing Work Derivative Works thereof, may choose offer, charge fee , acceptance support, warranty, indemnity, liability obligations /rights consistent License. However, accepting obligations, may act behalf sole responsibility, behalf Contributor, agree indemnify, defend, hold Contributor harmless liability incurred , claims asserted , Contributor reason accepting warranty additional liability. END TERMS CONDITIONS","code":""},{"path":"https://ahasoplakus.github.io/clinTables/LICENSE.html","id":"appendix-how-to-apply-the-apache-license-to-your-work","dir":"","previous_headings":"","what":"APPENDIX: How to apply the Apache License to your work","title":"Apache License","text":"apply Apache License work, attach following boilerplate notice, fields enclosed brackets [] replaced identifying information. (Don’t include brackets!) text enclosed appropriate comment syntax file format. also recommend file class name description purpose included “printed page” copyright notice easier identification within third-party archives.","code":"Copyright [yyyy] [name of copyright owner]  Licensed under the Apache License, Version 2.0 (the \"License\"); you may not use this file except in compliance with the License. You may obtain a copy of the License at    http://www.apache.org/licenses/LICENSE-2.0  Unless required by applicable law or agreed to in writing, software distributed under the License is distributed on an \"AS IS\" BASIS, WITHOUT WARRANTIES OR CONDITIONS OF ANY KIND, either express or implied. See the License for the specific language governing permissions and limitations under the License."},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae_by_sev_tox.html","id":null,"dir":"Reference","previous_headings":"","what":"Adverse Events Table by Body System and Severity/Toxicity — adae_by_sev_tox","title":"Adverse Events Table by Body System and Severity/Toxicity — adae_by_sev_tox","text":"Adverse Events Table Body System Severity/Toxicity","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae_by_sev_tox.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Adverse Events Table by Body System and Severity/Toxicity — adae_by_sev_tox","text":"","code":"adae_by_sev_tox(   adsl,   df_adae,   colsby = \"ARM\",   grade_val = \"AESEV\",   class_val = \"AESOC\",   term_val = \"AEDECOD\",   default_view = TRUE )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae_by_sev_tox.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Adverse Events Table by Body System and Severity/Toxicity — adae_by_sev_tox","text":"adsl Input ADSL data df_adae Input ADAE data colsby Column Variable (default: ARM) grade_val AE Severity AE Toxicity Grade .e. AESEV AETOXGR class_val Sytem Organ Class/Body System Class .e. AESOC AEBODSYS term_val Dictionary Derived Term .e. AEDECOD AETERM default_view Logical TRUE FALSE","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae_by_sev_tox.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Adverse Events Table by Body System and Severity/Toxicity — adae_by_sev_tox","text":"rtable object","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/adae_by_sev_tox.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Adverse Events Table by Body System and Severity/Toxicity — adae_by_sev_tox","text":"","code":"adsl <- random.cdisc.data::cadsl adae <- random.cdisc.data::cadae  ae_by_sev_tox_table <- adae_by_sev_tox(   adsl = adsl,   df_adae = adae,   colsby = \"ARM\",   grade_val = \"AESEV\",   class_val = \"AESOC\",   term_val = \"AEDECOD\",   default_view = TRUE )  ae_by_sev_tox_table #> Primary System Organ Class                         A: Drug X (N = 134)                                 B: Placebo (N = 134)                              C: Combination (N = 132)       #>     Dictionary-Derived Term       N           MILD       MODERATE      SEVERE         N           MILD       MODERATE      SEVERE         N           MILD       MODERATE      SEVERE   #> --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- #> cl A                                                                                                                                                                                    #>   dcd A.1.1.1.1               50 (37.3%)   50 (37.3%)       0            0        45 (33.6%)   45 (33.6%)       0            0        63 (47.7%)   63 (47.7%)       0            0      #>   dcd A.1.1.1.2               48 (35.8%)       0        48 (35.8%)       0        48 (35.8%)       0        48 (35.8%)       0        50 (37.9%)       0        50 (37.9%)       0      #> cl B                                                                                                                                                                                    #>   dcd B.1.1.1.1               47 (35.1%)       0            0        47 (35.1%)   49 (36.6%)       0            0        49 (36.6%)   43 (32.6%)       0            0        43 (32.6%) #>   dcd B.2.1.2.1               49 (36.6%)       0        49 (36.6%)       0        44 (32.8%)       0        44 (32.8%)       0        52 (39.4%)       0        52 (39.4%)       0      #>   dcd B.2.2.3.1               48 (35.8%)   48 (35.8%)       0            0        54 (40.3%)   54 (40.3%)       0            0        51 (38.6%)   51 (38.6%)       0            0      #> cl C                                                                                                                                                                                    #>   dcd C.1.1.1.3               43 (32.1%)       0            0        43 (32.1%)   46 (34.3%)       0            0        46 (34.3%)   43 (32.6%)       0            0        43 (32.6%) #>   dcd C.2.1.2.1               35 (26.1%)       0        35 (26.1%)       0        48 (35.8%)       0        48 (35.8%)       0        55 (41.7%)       0        55 (41.7%)       0      #> cl D                                                                                                                                                                                    #>   dcd D.1.1.1.1               50 (37.3%)       0            0        50 (37.3%)   42 (31.3%)       0            0        42 (31.3%)   51 (38.6%)       0            0        51 (38.6%) #>   dcd D.1.1.4.2               48 (35.8%)       0        48 (35.8%)       0        42 (31.3%)       0        42 (31.3%)       0        50 (37.9%)       0        50 (37.9%)       0      #>   dcd D.2.1.5.3               47 (35.1%)   47 (35.1%)       0            0        58 (43.3%)   58 (43.3%)       0            0        57 (43.2%)   57 (43.2%)       0            0"},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":null,"dir":"Reference","previous_headings":"","what":"Add Flags to ADAE — add_adae_flags","title":"Add Flags to ADAE — add_adae_flags","text":"Add Flags ADAE","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Add Flags to ADAE — add_adae_flags","text":"","code":"add_adae_flags(df)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Add Flags to ADAE — add_adae_flags","text":"df (data.frame) ADAE dataset.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Add Flags to ADAE — add_adae_flags","text":"ADAE dataset added flags","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/add_adae_flags.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Add Flags to ADAE — add_adae_flags","text":"USUBJID FATAL SER SERWD SERDSM RELSER WD DSM REL RELWD RELDSM CTC35 CTC45 AB12345-BRA-1-id-134 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE AB12345-BRA-1-id-134 FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE AB12345-BRA-1-id-134 FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE FALSE AB12345-BRA-1-id-134 FALSE TRUE TRUE FALSE FALSE TRUE FALSE FALSE FALSE FALSE FALSE FALSE AB12345-BRA-1-id-141 FALSE FALSE FALSE FALSE FALSE FALSE TRUE FALSE FALSE FALSE TRUE FALSE","code":"library(dplyr) #>  #> Attaching package: 'dplyr' #> The following objects are masked from 'package:stats': #>  #>     filter, lag #> The following objects are masked from 'package:base': #>  #>     intersect, setdiff, setequal, union adsl <- random.cdisc.data::cadsl adae <- random.cdisc.data::cadae adae_ <- add_adae_flags(adae)  tbl <- select(adae_, c(\"USUBJID\", setdiff(names(adae_), names(adae))))  flextable::flextable(slice_head(tbl, n = 5)) .cl-f7106d3e{}.cl-f7080874{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-f70bb258{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-f70bb259{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-f70bb25a{width:0.75in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f70bb25b{width:0.75in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f70bb25c{width:0.75in;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f70bb25d{width:0.75in;background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f70bb25e{width:0.75in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f70bb25f{width:0.75in;background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}USUBJIDFATALSERSERWDSERDSMRELSERWDDSMRELRELWDRELDSMCTC35CTC45AB12345-BRA-1-id-134FALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSETRUEFALSEAB12345-BRA-1-id-134FALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSETRUEFALSEAB12345-BRA-1-id-134FALSETRUEFALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSEFALSEAB12345-BRA-1-id-134FALSETRUETRUEFALSEFALSETRUEFALSEFALSEFALSEFALSEFALSEFALSEAB12345-BRA-1-id-141FALSEFALSEFALSEFALSEFALSEFALSETRUEFALSEFALSEFALSETRUEFALSE"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":null,"dir":"Reference","previous_headings":"","what":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"Adverse Events Table Body System Severity/Toxicity","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"","code":"build_adae_by_sev_tox(   adsl,   df_adae,   colsby = \"ARM\",   filter_cond = NULL,   grade_val = \"AESEV\",   class_val = \"AESOC\",   term_val = \"AEDECOD\",   default_view = TRUE )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"adsl (data.frame) ADSL dataset. df_adae (data.frame) ADAE dataset. colsby (character) Variable used split table columns. filter_cond (character) Filtering condition required df_adae. grade_val (character) AE Severity AE Toxicity Grade .e. AESEV AETOXGR class_val (character) System Organ Class/Body System Class .e. AESOC AEBODSYS term_val (character) Dictionary Derived Term .e. AEDECOD AETERM default_view (logical)TRUE displays values grade_val columns.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"rtable object","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_by_sev_tox.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Adverse Events Table by Body System and Severity/Toxicity — build_adae_by_sev_tox","text":"Primary System Organ Class  : Drug X (N = 134)  B: Placebo (N = 134)  C: Combination (N = 132) Dictionary-Derived Term N MILD MODERATE SEVERE N MILD MODERATE SEVERE N MILD MODERATE SEVERE cl             dcd .1.1.1.1 50 (37.3%) 50 (37.3%) 0 0 45 (33.6%) 45 (33.6%) 0 0 63 (47.7%) 63 (47.7%) 0 0 dcd .1.1.1.2 48 (35.8%) 0 48 (35.8%) 0 48 (35.8%) 0 48 (35.8%) 0 50 (37.9%) 0 50 (37.9%) 0 cl B             dcd B.1.1.1.1 47 (35.1%) 0 0 47 (35.1%) 49 (36.6%) 0 0 49 (36.6%) 43 (32.6%) 0 0 43 (32.6%) dcd B.2.1.2.1 49 (36.6%) 0 49 (36.6%) 0 44 (32.8%) 0 44 (32.8%) 0 52 (39.4%) 0 52 (39.4%) 0 dcd B.2.2.3.1 48 (35.8%) 48 (35.8%) 0 0 54 (40.3%) 54 (40.3%) 0 0 51 (38.6%) 51 (38.6%) 0 0 cl C             dcd C.1.1.1.3 43 (32.1%) 0 0 43 (32.1%) 46 (34.3%) 0 0 46 (34.3%) 43 (32.6%) 0 0 43 (32.6%) dcd C.2.1.2.1 35 (26.1%) 0 35 (26.1%) 0 48 (35.8%) 0 48 (35.8%) 0 55 (41.7%) 0 55 (41.7%) 0 cl D             dcd D.1.1.1.1 50 (37.3%) 0 0 50 (37.3%) 42 (31.3%) 0 0 42 (31.3%) 51 (38.6%) 0 0 51 (38.6%) dcd D.1.1.4.2 48 (35.8%) 0 48 (35.8%) 0 42 (31.3%) 0 42 (31.3%) 0 50 (37.9%) 0 50 (37.9%) 0 dcd D.2.1.5.3 47 (35.1%) 47 (35.1%) 0 0 58 (43.3%) 58 (43.3%) 0 0 57 (43.2%) 57 (43.2%) 0 0","code":"adsl <- random.cdisc.data::cadsl adae <- random.cdisc.data::cadae  tbl <- build_adae_by_sev_tox(   adsl = adsl,   df_adae = adae,   colsby = \"ARM\",   grade_val = \"AESEV\",   class_val = \"AESOC\",   term_val = \"AEDECOD\",   default_view = TRUE )  rtables::tt_to_flextable(tbl) .cl-fc4f9270{table-layout:auto;}.cl-fc466c36{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fc466c37{font-family:'courier';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fc49c80e{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fc49c80f{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fc49c810{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:0;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fc49c811{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:10pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fc49eeec{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eeed{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eeee{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eeef{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eef0{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eef1{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eef2{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eef3{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eef4{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fc49eef5{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Primary System Organ ClassA: Drug X (N = 134)B: Placebo (N = 134)C: Combination (N = 132)    Dictionary-Derived TermNMILDMODERATESEVERENMILDMODERATESEVERENMILDMODERATESEVEREcl A  dcd A.1.1.1.150 (37.3%)50 (37.3%)0045 (33.6%)45 (33.6%)0063 (47.7%)63 (47.7%)00  dcd A.1.1.1.248 (35.8%)048 (35.8%)048 (35.8%)048 (35.8%)050 (37.9%)050 (37.9%)0cl B  dcd B.1.1.1.147 (35.1%)0047 (35.1%)49 (36.6%)0049 (36.6%)43 (32.6%)0043 (32.6%)  dcd B.2.1.2.149 (36.6%)049 (36.6%)044 (32.8%)044 (32.8%)052 (39.4%)052 (39.4%)0  dcd B.2.2.3.148 (35.8%)48 (35.8%)0054 (40.3%)54 (40.3%)0051 (38.6%)51 (38.6%)00cl C  dcd C.1.1.1.343 (32.1%)0043 (32.1%)46 (34.3%)0046 (34.3%)43 (32.6%)0043 (32.6%)  dcd C.2.1.2.135 (26.1%)035 (26.1%)048 (35.8%)048 (35.8%)055 (41.7%)055 (41.7%)0cl D  dcd D.1.1.1.150 (37.3%)0050 (37.3%)42 (31.3%)0042 (31.3%)51 (38.6%)0051 (38.6%)  dcd D.1.1.4.248 (35.8%)048 (35.8%)042 (31.3%)042 (31.3%)050 (37.9%)050 (37.9%)0  dcd D.2.1.5.347 (35.1%)47 (35.1%)0058 (43.3%)58 (43.3%)0057 (43.2%)57 (43.2%)00"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":null,"dir":"Reference","previous_headings":"","what":"Create ADAE Summary Table — build_adae_summary","title":"Create ADAE Summary Table — build_adae_summary","text":"Create ADAE Summary Table","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create ADAE Summary Table — build_adae_summary","text":"","code":"build_adae_summary(adae, filter_cond = NULL, event_vars, trt_var)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create ADAE Summary Table — build_adae_summary","text":"adae (data.frame) ADAE dataset. filter_cond (character) Filtering condition required adae. event_vars (vector character) Variables added source ADAE add_adae_flags(). trt_var (character) Arm variable used split table columns.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create ADAE Summary Table — build_adae_summary","text":"List containing layout object ADAE Summary Table filtered ADAE data","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adae_summary.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create ADAE Summary Table — build_adae_summary","text":": Drug X B: Placebo C: Combination Patients Adverse Events (N=134) (N=134) (N=132) (N=400) Total number patients least one adverse event 122 (91.0%) 123 (91.8%) 120 (90.9%) 365 (91.2%) Total AEs 609 622 703 1934 Total number patients least one     AE fatal outcome 76 (56.7%) 70 (52.2%) 75 (56.8%) 221 (55.2%) Serious AE 104 (77.6%) 101 (75.4%) 99 (75.0%) 304 (76.0%) Serious AE leading withdrawal treatment 9 (6.7%) 6 (4.5%) 11 (8.3%) 26 (6.5%) Serious AE leading dose modification/interruption 22 (16.4%) 26 (19.4%) 30 (22.7%) 78 (19.5%) Related Serious AE 76 (56.7%) 70 (52.2%) 75 (56.8%) 221 (55.2%) AE leading withdrawal treatment 27 (20.1%) 26 (19.4%) 30 (22.7%) 83 (20.8%) AE leading dose modification/interruption 66 (49.3%) 76 (56.7%) 74 (56.1%) 216 (54.0%) Related AE 105 (78.4%) 108 (80.6%) 109 (82.6%) 322 (80.5%) Related AE leading withdrawal treatment 6 (4.5%) 12 (9.0%) 8 (6.1%) 26 (6.5%) Related AE leading dose modification/interruption 29 (21.6%) 38 (28.4%) 38 (28.8%) 105 (26.2%) Grade 3-5 AE 109 (81.3%) 104 (77.6%) 109 (82.6%) 322 (80.5%) Grade 4/5 AE 91 (67.9%) 90 (67.2%) 93 (70.5%) 274 (68.5%)","code":"library(rtables) #> Loading required package: formatters #> Loading required package: magrittr #> Warning: package 'magrittr' was built under R version 4.1.3 adsl <- random.cdisc.data::cadsl adae <- random.cdisc.data::cadae adae_ <- add_adae_flags(adae) lyt <- build_adae_summary(   adae = adae_,   filter_cond = NULL,   event_vars = setdiff(names(adae_), names(adae)),   trt_var = \"ARM\" ) tbl <- build_table(lyt = lyt$lyt, df = lyt$df_out, alt_counts_df = adsl)  rtables::tt_to_flextable(tbl) .cl-fdee0e22{table-layout:auto;}.cl-fddd9d4e{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fddd9d4f{font-family:'courier';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fde32ce6{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fde32ce7{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fde32ce8{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:0;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fde32ce9{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:10pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fde353ce{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353cf{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d0{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d1{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d2{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d3{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d4{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d5{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d6{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d7{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde353d8{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b7e{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b7f{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b80{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b81{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b82{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b83{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b84{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b85{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fde37b86{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}A: Drug XB: PlaceboC: CombinationAll PatientsAdverse Events(N=134)(N=134)(N=132)(N=400)Total number of patients with at least one adverse event122 (91.0%)123 (91.8%)120 (90.9%)365 (91.2%)Total AEs6096227031934Total number of patients with at least one  AE with fatal outcome76 (56.7%)70 (52.2%)75 (56.8%)221 (55.2%)  Serious AE104 (77.6%)101 (75.4%)99 (75.0%)304 (76.0%)  Serious AE leading to withdrawal from treatment9 (6.7%)6 (4.5%)11 (8.3%)26 (6.5%)  Serious AE leading to dose modification/interruption22 (16.4%)26 (19.4%)30 (22.7%)78 (19.5%)  Related Serious AE76 (56.7%)70 (52.2%)75 (56.8%)221 (55.2%)  AE leading to withdrawal from treatment27 (20.1%)26 (19.4%)30 (22.7%)83 (20.8%)  AE leading to dose modification/interruption66 (49.3%)76 (56.7%)74 (56.1%)216 (54.0%)  Related AE105 (78.4%)108 (80.6%)109 (82.6%)322 (80.5%)  Related AE leading to withdrawal from treatment6 (4.5%)12 (9.0%)8 (6.1%)26 (6.5%)  Related AE leading to dose modification/interruption29 (21.6%)38 (28.4%)38 (28.8%)105 (26.2%)  Grade 3-5 AE109 (81.3%)104 (77.6%)109 (82.6%)322 (80.5%)  Grade 4/5 AE91 (67.9%)90 (67.2%)93 (70.5%)274 (68.5%)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl.html","id":null,"dir":"Reference","previous_headings":"","what":"Build adsl dataset — build_adsl","title":"Build adsl dataset — build_adsl","text":"function build demographic table full set","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Build adsl dataset — build_adsl","text":"","code":"build_adsl(   title = \"x.x: Study Subject Data\",   subtitle = c(\"x.x.x: Demographic Characteristics\",     \"Table x.x.x.x: Demographic Characteristics - Full Analysis Set\"),   footer = \"Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY\",   split_cols_by = \"ARM\",   summ_vars = c(\"AGE\", \"SEX\", \"COUNTRY\") )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Build adsl dataset — build_adsl","text":"title (character) Title demographic table. subtitle (character) Subtitle demographic table. footer (character) Footer demographic table. split_cols_by (character) Arm variable used split table columns. summ_vars (character) Variables df include table.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Build adsl dataset — build_adsl","text":"tabletree object.","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Build adsl dataset — build_adsl","text":"","code":"lyt <- build_adsl(   split_cols_by = \"ARM\",   summ_vars = c(\"AGE\", \"RACE\") )   ## Use the tabletree object to within build_table rtables::build_table(lyt, random.cdisc.data::cadsl) #> x.x: Study Subject Data #> x.x.x: Demographic Characteristics #> Table x.x.x.x: Demographic Characteristics - Full Analysis Set #>  #> ------------------------------------------------------------------------------------------------------- #>                                                A: Drug X    B: Placebo    C: Combination   All Patients #> Characteristic                                  (N=134)       (N=134)        (N=132)         (N=400)    #> ------------------------------------------------------------------------------------------------------- #> AGE                                                                                                     #>   n                                               134           134            132             400      #>   Mean, SD                                    33.8 (6.6)    35.4 (7.9)      35.4 (7.7)      34.9 (7.4)  #>   Standard Error                                  0.6           0.7            0.7             0.4      #>   Median                                         33.0          35.0            35.0            34.0     #>   Min-Max                                     21.0 - 50.0   21.0 - 62.0    20.0 - 69.0     20.0 - 69.0  #>   IQR                                         28.0 - 39.0   30.0 - 40.0    30.0 - 40.0     29.0 - 39.0  #> RACE                                                                                                    #>   n                                               134           134            132             400      #>   ASIAN                                       68 (50.7%)     67 (50%)       73 (55.3%)      208 (52%)   #>   BLACK OR AFRICAN AMERICAN                   31 (23.1%)    28 (20.9%)      32 (24.2%)      91 (22.8%)  #>   WHITE                                       27 (20.1%)    26 (19.4%)      21 (15.9%)      74 (18.5%)  #>   AMERICAN INDIAN OR ALASKA NATIVE              8 (6%)       11 (8.2%)       6 (4.5%)       25 (6.2%)   #>   MULTIPLE                                         0         1 (0.7%)           0            1 (0.2%)   #>   NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER        0         1 (0.7%)           0            1 (0.2%)   #>   OTHER                                            0             0              0               0       #>   UNKNOWN                                          0             0              0               0       #> ------------------------------------------------------------------------------------------------------- #>  #> Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":null,"dir":"Reference","previous_headings":"","what":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"Baseline Demographic Clinical Characteristics","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"","code":"build_adsl_chars_table(   title = \"x.x: Study Subject Data\",   subtitle = c(\"x.x.x: Demographic Characteristics\",     \"Table x.x.x.x: Demographic Characteristics - Full Analysis Set\"),   footer = \"Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY\",   split_cols_by = \"ARM\",   summ_vars = c(\"AGE\", \"SEX\", \"COUNTRY\"),   disp_stat = c(\"n\", \"mean_sd\", \"se\", \"median\", \"range\", \"quantiles\", \"count_fraction\") )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"title (character) Title demographic table. subtitle (character) Subtitle demographic table. footer (character) Footer demographic table. split_cols_by (character) Arm variable used split table columns. summ_vars (vector character) Variables df include table. disp_stat (vector character) Statistics display.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"tabletree object.","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_adsl_chars_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Baseline Demographic and Clinical Characteristics — build_adsl_chars_table","text":"Table x.x.x.x: Demographic Characteristics - Full Analysis Set x.x.x: Demographic Characteristics x.x: Study Subject Data  : Drug X B: Placebo C: Combination Patients Characteristic (N=134) (N=134) (N=132) (N=400) AGE     n 134 134 132 400 Mean, SD 33.8 (6.6) 35.4 (7.9) 35.4 (7.7) 34.9 (7.4) Standard Error 0.6 0.7 0.7 0.4 Median 33.0 35.0 35.0 34.0 Min-Max 21.0 - 50.0 21.0 - 62.0 20.0 - 69.0 20.0 - 69.0 IQR 28.0 - 39.0 30.0 - 40.0 30.0 - 40.0 29.0 - 39.0 RACE     n 134 134 132 400 ASIAN 68 (50.7%) 67 (50%) 73 (55.3%) 208 (52%) BLACK AFRICAN AMERICAN 31 (23.1%) 28 (20.9%) 32 (24.2%) 91 (22.8%) WHITE 27 (20.1%) 26 (19.4%) 21 (15.9%) 74 (18.5%) AMERICAN INDIAN ALASKA NATIVE 8 (6%) 11 (8.2%) 6 (4.5%) 25 (6.2%) MULTIPLE 0 1 (0.7%) 0 1 (0.2%) NATIVE HAWAIIAN PACIFIC ISLANDER 0 1 (0.7%) 0 1 (0.2%) 0 0 0 0 UNKNOWN 0 0 0 0 Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY","code":"lyt <- build_adsl_chars_table(   split_cols_by = \"ARM\",   summ_vars = c(\"AGE\", \"RACE\") ) tbl <- rtables::build_table(lyt, random.cdisc.data::cadsl)  rtables::tt_to_flextable(tbl) .cl-ff14ebcc{table-layout:auto;}.cl-ff048f16{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-ff048f17{font-family:'courier';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-ff0ac48a{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-ff0ac48b{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-ff0ac48c{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:0;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-ff0ac48d{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:10pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-ff0aeb90{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb91{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb92{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb93{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb94{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb95{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb96{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb97{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb98{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb99{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0aeb9a{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12b4{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12b5{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12b6{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12b7{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12b8{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12b9{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12ba{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12bb{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12bc{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12bd{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b12be{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39ba{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39bb{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39bc{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39bd{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39be{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39bf{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39c0{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39c1{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39c2{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39c3{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b39c4{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b60ca{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b60cb{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b60cc{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b60cd{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b60ce{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b60cf{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-ff0b60d0{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Table x.x.x.x: Demographic Characteristics - Full Analysis Setx.x.x: Demographic Characteristicsx.x: Study Subject DataA: Drug XB: PlaceboC: CombinationAll PatientsCharacteristic(N=134)(N=134)(N=132)(N=400)AGE  n134134132400  Mean, SD33.8 (6.6)35.4 (7.9)35.4 (7.7)34.9 (7.4)  Standard Error0.60.70.70.4  Median33.035.035.034.0  Min-Max21.0 - 50.021.0 - 62.020.0 - 69.020.0 - 69.0  IQR28.0 - 39.030.0 - 40.030.0 - 40.029.0 - 39.0RACE  n134134132400  ASIAN68 (50.7%)67 (50%)73 (55.3%)208 (52%)  BLACK OR AFRICAN AMERICAN31 (23.1%)28 (20.9%)32 (24.2%)91 (22.8%)  WHITE27 (20.1%)26 (19.4%)21 (15.9%)74 (18.5%)  AMERICAN INDIAN OR ALASKA NATIVE8 (6%)11 (8.2%)6 (4.5%)25 (6.2%)  MULTIPLE01 (0.7%)01 (0.2%)  NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER01 (0.7%)01 (0.2%)  OTHER0000  UNKNOWN0000Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_demog_characteristics_table.html","id":null,"dir":"Reference","previous_headings":"","what":"Baseline Demographic and Clinical Characteristics — build_demog_characteristics_table","title":"Baseline Demographic and Clinical Characteristics — build_demog_characteristics_table","text":"Baseline Demographic Clinical Characteristics","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_demog_characteristics_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Baseline Demographic and Clinical Characteristics — build_demog_characteristics_table","text":"","code":"build_demog_characteristics_table(   title = \"x.x: Study Subject Data\",   subtitle = c(\"x.x.x: Demographic Characteristics\",     \"Table x.x.x.x: Demographic Characteristics - Full Analysis Set\"),   footer = \"Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY\",   split_cols_by = \"ARM\",   summ_vars = c(\"AGE\", \"SEX\", \"COUNTRY\") )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_demog_characteristics_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Baseline Demographic and Clinical Characteristics — build_demog_characteristics_table","text":"title (character) Title demographic table. subtitle (character) Subtitle demographic table. footer (character) Footer demographic table. split_cols_by (character) Arm variable used split table columns. summ_vars (vector character) Variables df include table.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_demog_characteristics_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Baseline Demographic and Clinical Characteristics — build_demog_characteristics_table","text":"tabletree object.","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_demog_characteristics_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Baseline Demographic and Clinical Characteristics — build_demog_characteristics_table","text":"","code":"lyt <- build_demog_characteristics_table(   split_cols_by = \"ARM\",   summ_vars = c(\"AGE\", \"RACE\") )   ## Use the tabletree object to within build_table rtables::build_table(lyt, random.cdisc.data::cadsl) #> x.x: Study Subject Data #> x.x.x: Demographic Characteristics #> Table x.x.x.x: Demographic Characteristics - Full Analysis Set #>  #> ------------------------------------------------------------------------------------------------------- #>                                                A: Drug X    B: Placebo    C: Combination   All Patients #> Characteristic                                  (N=134)       (N=134)        (N=132)         (N=400)    #> ------------------------------------------------------------------------------------------------------- #> AGE                                                                                                     #>   n                                               134           134            132             400      #>   Mean, SD                                    33.8 (6.6)    35.4 (7.9)      35.4 (7.7)      34.9 (7.4)  #>   Standard Error                                  0.6           0.7            0.7             0.4      #>   Median                                         33.0          35.0            35.0            34.0     #>   Min-Max                                     21.0 - 50.0   21.0 - 62.0    20.0 - 69.0     20.0 - 69.0  #>   IQR                                         28.0 - 39.0   30.0 - 40.0    30.0 - 40.0     29.0 - 39.0  #> RACE                                                                                                    #>   n                                               134           134            132             400      #>   ASIAN                                       68 (50.7%)     67 (50%)       73 (55.3%)      208 (52%)   #>   BLACK OR AFRICAN AMERICAN                   31 (23.1%)    28 (20.9%)      32 (24.2%)      91 (22.8%)  #>   WHITE                                       27 (20.1%)    26 (19.4%)      21 (15.9%)      74 (18.5%)  #>   AMERICAN INDIAN OR ALASKA NATIVE              8 (6%)       11 (8.2%)       6 (4.5%)       25 (6.2%)   #>   MULTIPLE                                         0         1 (0.7%)           0            1 (0.2%)   #>   NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER        0         1 (0.7%)           0            1 (0.2%)   #>   OTHER                                            0             0              0               0       #>   UNKNOWN                                          0             0              0               0       #> ------------------------------------------------------------------------------------------------------- #>  #> Source: ADSL DDMMYYYY hh:mm; Listing x.xx; SDTM package: DDMMYYYY"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":null,"dir":"Reference","previous_headings":"","what":"Create Generic Occurrence Table — build_generic_occurrence_table","title":"Create Generic Occurrence Table — build_generic_occurrence_table","text":"Create Generic Occurrence Table","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create Generic Occurrence Table — build_generic_occurrence_table","text":"","code":"build_generic_occurrence_table(   occ_df,   filter_cond = NULL,   trt_var,   dataset,   class_var,   term_var )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create Generic Occurrence Table — build_generic_occurrence_table","text":"occ_df (data.frame) Occurrence dataset (typically ADAE, ADMH etc) required build table. filter_cond (character) Filtering condition required occ_df. trt_var (character) Arm variable used split table columns. dataset (character) Name dataset eg. \"cadae\". class_var (character) Body system organ class variable. term_var (character) Preferred term variable occ_df include table.","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create Generic Occurrence Table — build_generic_occurrence_table","text":"List containing table layout object Generic Occurrence Table filtered Occurrencedata","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/build_generic_occurrence_table.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create Generic Occurrence Table — build_generic_occurrence_table","text":"Primary System Organ Class : Drug X B: Placebo C: Combination Patients Dictionary-Derived Term (N=134) (N=134) (N=132) (N=400) Total number patients least one event 122 (91.0%) 123 (91.8%) 120 (90.9%) 365 (91.2%) Total number events 609 622 703 1934 cl 78 (58.2%) 75 (56.0%) 89 (67.4%) 242 (60.5%) dcd .1.1.1.1 50 (37.3%) 45 (33.6%) 63 (47.7%) 158 (39.5%) dcd .1.1.1.2 48 (35.8%) 48 (35.8%) 50 (37.9%) 146 (36.5%) cl B 96 (71.6%) 89 (66.4%) 97 (73.5%) 282 (70.5%) dcd B.1.1.1.1 47 (35.1%) 49 (36.6%) 43 (32.6%) 139 (34.8%) dcd B.2.1.2.1 49 (36.6%) 44 (32.8%) 52 (39.4%) 145 (36.2%) dcd B.2.2.3.1 48 (35.8%) 54 (40.3%) 51 (38.6%) 153 (38.2%) cl C 67 (50.0%) 75 (56.0%) 79 (59.8%) 221 (55.2%) dcd C.1.1.1.3 43 (32.1%) 46 (34.3%) 43 (32.6%) 132 (33.0%) dcd C.2.1.2.1 35 (26.1%) 48 (35.8%) 55 (41.7%) 138 (34.5%) cl D 96 (71.6%) 90 (67.2%) 98 (74.2%) 284 (71.0%) dcd D.1.1.1.1 50 (37.3%) 42 (31.3%) 51 (38.6%) 143 (35.8%) dcd D.1.1.4.2 48 (35.8%) 42 (31.3%) 50 (37.9%) 140 (35.0%) dcd D.2.1.5.3 47 (35.1%) 58 (43.3%) 57 (43.2%) 162 (40.5%)","code":"library(rtables) library(tern) library(dplyr) adsl <- random.cdisc.data::cadsl adae <- random.cdisc.data::cadae adae <- filter(adae, SAFFL == \"Y\")  lyt <- build_generic_occurrence_table(   occ_df = adae,   filter_cond = NULL,   trt_var = \"ARM\",   dataset = \"cadae\",   class_var = \"AESOC\",   term_var = \"AEDECOD\" ) tbl <- build_table(lyt = lyt$lyt, df = lyt$df_out, alt_counts_df = adsl)  rtables::tt_to_flextable(tbl) .cl-0033954e{table-layout:auto;}.cl-0021931c{font-family:'Arial';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-0021931d{font-family:'courier';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-0028828a{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-0028828b{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-0028828c{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:0;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-0028828d{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:10pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-0028828e{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:20pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-0028a6a2{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6a3{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6a4{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6a5{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1.5pt solid rgba(102, 102, 102, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6a6{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6a7{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6a8{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6a9{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6aa{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6ab{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028a6ac{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028cde4{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028cde5{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028cde6{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028cde7{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-0028cde8{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}Primary System Organ ClassA: Drug XB: PlaceboC: CombinationAll Patients  Dictionary-Derived Term(N=134)(N=134)(N=132)(N=400)Total number of patients with at least one event122 (91.0%)123 (91.8%)120 (90.9%)365 (91.2%)Total number of events6096227031934  cl A78 (58.2%)75 (56.0%)89 (67.4%)242 (60.5%)    dcd A.1.1.1.150 (37.3%)45 (33.6%)63 (47.7%)158 (39.5%)    dcd A.1.1.1.248 (35.8%)48 (35.8%)50 (37.9%)146 (36.5%)  cl B96 (71.6%)89 (66.4%)97 (73.5%)282 (70.5%)    dcd B.1.1.1.147 (35.1%)49 (36.6%)43 (32.6%)139 (34.8%)    dcd B.2.1.2.149 (36.6%)44 (32.8%)52 (39.4%)145 (36.2%)    dcd B.2.2.3.148 (35.8%)54 (40.3%)51 (38.6%)153 (38.2%)  cl C67 (50.0%)75 (56.0%)79 (59.8%)221 (55.2%)    dcd C.1.1.1.343 (32.1%)46 (34.3%)43 (32.6%)132 (33.0%)    dcd C.2.1.2.135 (26.1%)48 (35.8%)55 (41.7%)138 (34.5%)  cl D96 (71.6%)90 (67.2%)98 (74.2%)284 (71.0%)    dcd D.1.1.1.150 (37.3%)42 (31.3%)51 (38.6%)143 (35.8%)    dcd D.1.1.4.248 (35.8%)42 (31.3%)50 (37.9%)140 (35.0%)    dcd D.2.1.5.347 (35.1%)58 (43.3%)57 (43.2%)162 (40.5%)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/clinTables-package.html","id":null,"dir":"Reference","previous_headings":"","what":"clinTables: Clinical Trial Tables in R — clinTables-package","title":"clinTables: Clinical Trial Tables in R — clinTables-package","text":"Shiny Application visualizing standard tables used Clinical Trials.","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/reference/clinTables-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"clinTables: Clinical Trial Tables in R — clinTables-package","text":"Maintainer: Sukalpo Saha sukalposaha@gmail.com","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/filters_to_cond.html","id":null,"dir":"Reference","previous_headings":"","what":"Create filtering condition based on filters — filters_to_cond","title":"Create filtering condition based on filters — filters_to_cond","text":"Create filtering condition based filters","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/filters_to_cond.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create filtering condition based on filters — filters_to_cond","text":"","code":"filters_to_cond(filter_list)"},{"path":"https://ahasoplakus.github.io/clinTables/reference/filters_to_cond.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create filtering condition based on filters — filters_to_cond","text":"filter_list (list) Named list filter values","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/filters_to_cond.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create filtering condition based on filters — filters_to_cond","text":"Filtering condition","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/filters_to_cond.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create filtering condition based on filters — filters_to_cond","text":"","code":"filter_list <- list(SEX = c(\"F\", \"M\")) filters_to_cond(filter_list) #> SEX %in% c('F','M')"},{"path":"https://ahasoplakus.github.io/clinTables/reference/run_app.html","id":null,"dir":"Reference","previous_headings":"","what":"Run the Shiny Application — run_app","title":"Run the Shiny Application — run_app","text":"Run Shiny Application","code":""},{"path":"https://ahasoplakus.github.io/clinTables/reference/run_app.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Run the Shiny Application — run_app","text":"","code":"run_app(   onStart = NULL,   options = list(),   enableBookmarking = NULL,   uiPattern = \"/\",   ... )"},{"path":"https://ahasoplakus.github.io/clinTables/reference/run_app.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Run the Shiny Application — run_app","text":"onStart function called app actually run. needed shinyAppObj, since shinyAppDir case, global.R file can used purpose. options Named options passed runApp call (can following: \"port\", \"launch.browser\", \"host\", \"quiet\", \"display.mode\" \"test.mode\"). can also specify width height parameters provide hint embedding environment ideal height/width app. enableBookmarking Can one \"url\", \"server\", \"disable\". default value, NULL, respect setting previous calls  enableBookmarking(). See enableBookmarking() information bookmarking app. uiPattern regular expression applied GET request determine whether ui used handle request. Note entire request path must match regular expression order match considered successful. ... arguments pass golem_opts. See ?golem::get_golem_options details.","code":""},{"path":[]},{"path":"https://ahasoplakus.github.io/clinTables/news/index.html","id":"clintables-0009000","dir":"Changelog","previous_headings":"","what":"clinTables 0.0.0.9000","title":"clinTables 0.0.0.9000","text":"Added NEWS.md file track changes package.","code":""}]
